Skip to main content

Triastek

ApplicationNanjing, ChinaFounded 2015· One of 686 Application companies tracked by AMPulse

Triastek is developing innovative 3D printed pharmaceuticals that revolutionize oral drug delivery by enhancing formulation efficiency and optimizing drug release profiles.

CEO / Founder
Senping Cheng
Team Size
11-50
Stage
Active
Total Funding
$122.4M
Latest Round
Series C
Key Investors
Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Xiaodong Zheng, Matrix Partners China (经纬中国), CPE, Shanghai Sci-Tech Innovation Center Capital, Triwise Capital, Goldmine Multi-family Office

Technology & Products

Key Products

3D printed pharmaceuticals, Melt Extrusion Deposition (MED) process, three IND (Investigational New Drug) applications filed.

Technological Advantage

Enables continuous, customizable tablet fabrication improving drug absorption and stability while significantly reducing development timelines.

Patent position

Triastek has filed 39 patent families across all years, compared with 38 for Aprecia and 4 for FabRx. AMPulse analysis

Filing momentum
6 families filed 2022–2024, 18 in 2019–2021
Filed in
US 59%EP 33%WO 21%CN 15%
Named competitors, AM patent families
Aprecia 38FabRx 4

39 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Enhancing formulation development efficiency and optimizing drug release profiles through proprietary 3D printing technology.

How They Differentiate

First mover in continuous 3D printed drug manufacturing with unique tablet geometries and a strong focus on digital drug development.

Market & Competition

Target Customers

Pharmaceutical companies and patients seeking advanced drug delivery solutions

Industry Verticals

Pharmaceuticals, Healthcare, Drug Development, Manufacturing

Competitors

Aprecia Pharmaceuticals; FabRx

Growth & Milestones

Growth Metrics

Advanced multiple products into clinical stages with several FDA IND clearances

Major Milestones

FDA IND clearance for its 3D printed product T20G, Successful IND clearances for T19, T21, and T22, Collaboration and platform technology license agreement with BioNTech for oral RNA therapeutics, Completion of $20.4 million funding round

Notable Customers

BioNTech (research partnership for 3D-printed oral RNA therapeutics), Boehringer Ingelheim GmbH (partnership for novel drug development).

https://www.triastek.com

Recent coverage of Triastek

AM patents

AM-relevant patents linked to this company.

Patents
54
Granted
8
Families
39

Leading domains: process (53), application (38), equipment (32)

Filings by year: 2024: 1 · 2023: 5 · 2021: 1 · 2020: 13 · 2019: 10 · 2018: 12

  1. HIGH-THROUGHPUT AND HIGH-PRECISCION PHARMACEUTICAL ADDITIVE MANUFACTURING SYSTEM2021031824 · WO
  2. ORAL DRUG DOSAGE FORMS HAVING A DESIRED PK PROFILE AND METHODS OF DESIGNING AND PRODUCING THEREOF20210196638 · US
  3. DOSAGE FORMS WITH DESIRED RELEASE PROFILES AND METHODS OF DESIGNING AND MAKING THEREOF20190209468 · US
  4. CONTROLLED RELEASE DOSAGE FORM3452003 · EP
  5. PRECISION PHARMACEUTICAL 3D PRINTING DEVICE20250049723 · US

Funding rounds

  • Pre-Series C$20.4M2023-09-28
  • Series B$20.5M2023-09-28Lead: Guoxin Investment
  • Series B$51.0M2021-06-22Lead: Matrix Partners China
  • Series A$15.3M2020-12-15Lead: Dalton Venture

Why this company matters

AMPulse analysis, not a company disclosure

Triastek occupies a distinctive position at the intersection of additive manufacturing and pharmaceutical development, focusing on oral solid dosage forms rather than medical devices or bioprinting. Its proprietary Melt Extrusion Deposition (MED) process enables continuous fabrication of tablets with controlled internal geometries that modulate drug release profiles, a capability that conventional compression or molding cannot replicate. This positions the company as a first mover in continuous 3D printed drug manufacturing, differentiated from earlier entrants such as Aprecia Pharmaceuticals and FabRx.

The MED process combines melt extrusion with layer-by-layer deposition, allowing precise control over porosity, density, and dissolution characteristics within a single tablet. Triastek has filed three Investigational New Drug applications with the FDA and received IND clearances for products including T20G, T19, T21, and T22. The company has also entered a research partnership with BioNTech to develop 3D-printed oral RNA therapeutics, extending its platform beyond small molecules into biologics.

Triastek targets pharmaceutical companies seeking to accelerate formulation development and improve bioavailability of poorly soluble compounds. Partnerships with Boehringer Ingelheim, Eli Lilly, Merck, and Siemens suggest the platform is being evaluated across multiple therapeutic areas. The company has raised approximately $122.4 million from investors including Tasly Holding Group, Morningside Venture Capital, and Matrix Partners China.

A key open question is whether the MED platform can achieve the throughput and cost parity required for blockbuster drug production, or whether it will remain a niche tool for high-value, low-volume therapies. The BioNTech collaboration for oral RNA therapeutics, if successful, could open a new category and validate the technology beyond conventional small molecules.